Bank of America Securities has upgraded BioNTech (Nasdaq: BNTX) to Buy raising the price target from $75 to $105

The stock opened at $92, up $3.80.  Yesterday, the Germany-based biotechnology company and Pfizer jointly announced positive preliminary results from early-stage testing of COVID-19 vaccine candidate BNT162b1. They also announced a deal to supply 30 million doses of their COVID-19 vaccine candidate to the United Kingdom once they complete clinical testing and get regulatory approval.

Add a Comment

Your email address will not be published. Required fields are marked *